Crystal Dockery, DO
Family Medicine · Old Town, MENPI 1114347069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,707 and has fallen 99.0% since, to $17 in 2025. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$748
- Boehringer Ingelheim$385
- GSK$316
- Merck$312
- Lilly USA, LLC$262
- Pfizer$248
- plus $2K from 17 others
What the payments were for
- Food & beverage$3,776100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 40 | $748 |
| Boehringer Ingelheim | 36 | $385 |
| GSK | 25 | $316 |
| Merck | 24 | $312 |
| Lilly USA, LLC | 22 | $262 |
| Pfizer | 19 | $248 |
| AbbVie(2 entities) | 8 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $149 |
| Novo Nordisk | 10 | $138 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| Astellas Pharma US Inc | 4 | $90 |
| Teva Pharmaceuticals USA, Inc. | 7 | $88 |
| Biohaven Pharmaceuticals, Inc. | 4 | $88 |
| Eisai Inc. | 5 | $88 |
| Amgen | 5 | $87 |
| Johnson & Johnson | 5 | $75 |
| Amarin Pharma, Inc. | 4 | $68 |
| Antares Pharma, Inc. | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Abbott | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,782 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 111 | $143,085 |
| EliquisApixaban | 80 | $94,246 |
| TrulicityDulaglutide | 96 | $91,130 |
| MounjaroTirzepatide | 77 | $87,185 |
| OzempicSemaglutide | 45 | $48,595 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $38,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,436 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $15,083 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $11,641 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $11,415 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,734 |
| VascepaIcosapent Ethyl | 11 | $7,331 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $7,200 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,442 |
| Rosuvastatin Calcium | 181 | $3,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $262 | $178,316173 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $385 | $154,500134 claims |
| PfizerEliquis | $248 | $94,24680 claims |
| Novo NordiskOzempic | $138 | $48,59545 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $316 | $32,16948 claims |
| AstraZenecaSymbicort | $748 | $2,89016 claims |
| AbbVieArmour Thyroid | $237 | $84717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Old Town
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
- Julia McDonaldAugusta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.